

JAN 2002
PATENT & TRADEMARK OFFICE

ORIGINAL FILED

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231

Date: November 28, 2001 Susan Dolci
Susan Dolci

RECEIVED
FEB 26 2002
TECH CENTER 1600/2900
LL-170US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Rampal *et al.*

Examiner: TBA

Application No.: 09/941,970

Group Art Unit: TBA

Filing Date: August 29, 2001

For: CONTROLLED RELEASE FORMULATION OF
ERYTHROMYCIN OR A DERIVATIVE THEREOF

**CLAIM OF PRIORITY UNDER 35 USC §119
AND SUBMISSION OF PRIORITY DOCUMENT**


Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants, by and through their attorney, hereby claim the priority of Indian Patent Application No. 778/Del/2000 filed August 29, 2000, a certified copy of which is submitted herewith.

Respectfully submitted,

Rampal *et al.*

By: 
Jayadeep R. Deshmukh, Reg. No. 34,507

Date: November 28, 2001

Ranbaxy Pharmaceuticals Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5608
Fax: (609) 720-5663



**GOVERNMENT OF INDIA
MINISTRY OF COMMERCE & INDUSTRY,
PATENT OFFICE, DELHI BRANCH,
W-5, WEST PATEL NAGAR,
NEW DELHI-110 008.**

TECH CENTER 1600/23001

FEB 2 6 2002

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

I the undersigned being an officer duly authorized in accordance with the provision of the Patent Act, 1970 hereby certify that annexed hereto is the true copy of the Application and Complete Specification filed in connection with Application for Patent No.778/Del/2000 dated 29th August 2000.

Witness my hand this 9th day of November 2001.



(H.C. BAKSHI)

Deputy Controller of Patents & Designs.

07/8 001 000
29 AUG 2000
FORM 1

Govt. of India Patent
New Delhi
29 AUG 2000
2887
Vide Entry No. 2887 in the
Register of Patents.

THE PATENTS ACT, 1970
(39 of 1970)

APPLICATION FOR GRANT OF A PATENT

(See Sections 5 (2), 7, 54 and 135 and rule 33A)

1. We, **RANBAXY LABORATORIES LIMITED**, a Company incorporated under the Companies Act, 1956 of 19, Nehru Place, New Delhi - 110 019, India
2. hereby declare –
 - (a) that we are in possession of an invention titled "**PROCESS FOR THE PREPARATION OF A CONTROLLED RELEASE FORMULATION OF ERYTHROMYCIN OR A DERIVATIVE THEREOF**"
 - (b) that the Complete Specification relating to this invention is filed with this application.
 - (c) that there is no lawful ground of objection to the grant of a patent to us.
3. further declare that the inventors for the said invention are
 - a. **ASHOK RAMPAL**
 - b. **RAJEEV S. RAGHUVANSHI**
 - c. **MANOJ KUMAR**



of Ranbaxy Laboratories Limited, Plot No. 20, Sector – 18, Udyog Vihar Industrial Area, Gurgaon-122001 (Haryana), India, all Indian Nationals.

4. That we are the assignee or legal representative of the true and first inventors.
5. That our address for service in India is as follows:

DR. BRIJ KHERA
Associate Director – Intellectual Property
Ranbaxy Laboratories Limited
Plot No.20, Sector – 18,
Udyog Vihar Industrial Area,
Gurgaon – 122001 (Haryana).
INDIA.
Tel. No. (91-124) 342001 – 10
Fax No. (91-124) 342027

6. Following declaration was given by the inventors in the convention country:

We, **ASHOK RAMPAL, RAJEEV S. RAGHUVANSHI, MANOJ KUMAR**, of Ranbaxy Laboratories Limited, Plot No.20, Sector – 18, Udyog Vihar Industrial Area, Gurgaon –122001 (Haryana), India, all Indian Nationals, the true and first inventors for this invention in the convention country declare that the applicants herein, **Ranbaxy Laboratories Limited**, 19, Nehru Place, New Delhi – 110 019, India, is our assignee or legal representative.

- a. 
(ASHOK RAMPAL)
- b. 
(RAJEEV S. RAGHUVANSHI)
- c.
(MANOJ KUMAR)

7. That to the best of our knowledge, information and belief the fact and matters stated herein are correct and that there is no lawful ground of objection to the grant of patent to us on this application.
8. Followings are the attachment with the application:
- a. Complete Specification (3 copies)
- b. Drawings (3 copies)
- c. Statement and Undertaking on FORM – 3
- d. Fee Rs.5,000/- (Rupees Five Thousand only..) in cheque bearing No. 670411
dated : 19.8.2000 drawn on ~~ANZ~~ ^{ANZ} ~~Bank~~ ^{Gmiller} payable at New Delhi.

We request that a patent may be granted to us for the said invention.

Dated this 29TH day of August, 2000.

For Ranbaxy Laboratories Limited


(S K PATAWARI)
Company Secretary

FORM 2

The Patents Act, 1970
(39 of 1970)

07 78 0000

COMPLETE SPECIFICATION
(See Section 10)

29 AUG 2000

**PROCESS FOR THE PREPARATION OF A CONTROLLED
RELEASE FORMULATION OF ERYTHROMYCIN OR A
DERIVATIVE THEREOF**

ORIGINAL

RANBAXY LABORATORIES LIMITED
19, NEHRU PLACE, NEW DELHI - 110019

A Company incorporated under the Companies Act, 1956.

**The following specification particularly describes and ascertains the nature of
this invention and the manner in which it is to be performed:**

The present invention relates to a process for the preparation of a controlled release pharmaceutical composition suitable for once daily administration of erythromycin or a derivative thereof. More preferably, it relates to a process for the preparation of a controlled release pharmaceutical composition of clarithromycin suitable for once daily administration.

It is well known to those skilled in the art that the blood levels of drugs need to be maintained above a minimum effective level and below its minimum toxic level in order to obtain the desired therapeutic effects and to minimize side effects. Unfortunately, the pharmacokinetic properties (absorption, elimination and metabolism) of most drugs are such that they need to be administered three to four times a day. This kind of a dosing regimen is very inconvenient and leads to reduction in patient compliance. Reduction of dosing regimen from three times a day (tid) to twice daily (bid) to once a day results in increased convenience and comfort and therefore increased patient compliance. Controlled release formulations which are effective in maintaining the therapeutic blood levels over extended periods of time result in optimal therapy. They not only reduce the frequency of dosing, but they also reduce the severity and frequency of side effects, as they maintain substantially constant blood levels and avoid the fluctuations associated with the conventional immediate release formulations administered three to four times a day.

Erythromycin and its derivatives are known for their antibacterial activity against a number of organisms and are typically administered at least two to three times a day as immediate release compositions. In particular, the 6-O-methoxyerythromycin A (clarithromycin) which has been disclosed in US Patent No. 4,331,803 has to be administered at least twice daily for optimal effect.

Clarithromycin presents a peculiar problem for the formulator as it is soluble in the acidic pH of the stomach (pH 1-2) and upper part of the intestine (less than pH 5.0) but is very unstable at these pH conditions, and while its stability is good at alkaline pH of the large intestine (pH 6.0 to 8.0), its solubility is poor there. This results in poor bioavailability of clarithromycin.

US Patent No. US 5,705,190 assigned to Abbott Laboratories describes controlled release compositions for such poorly soluble basic drugs comprising a water soluble alginate salt,

a complex salt of alginic acid and an organic carboxylic acid to facilitate dissolution of the basic drug at a higher pH . The formulations as described in the specification of this patent have an area under the plasma concentration - time curve (AUC) and minimum plasma concentration (Cmin) values substantially similar to those obtained by the immediate release tablets given twice daily. The maximum plasma concentration (Cmax) values, however, did not show any reduction and were similar to those for immediate release formulations.

However, the total tablet weight of each tablet containing 500mg drug as described in the examples of this invention is more than 900 mg, as substantial amounts of polymers are required for controlling the rate of drug release. A single tablet containing 1000mg drug, when made according to this invention would weigh at least 1800mg. This would be unacceptably large for human consumption, and two tablets of 500mg strength each would be required for administering the daily adult dose of 1000mg clarithromycin.

US Patent No. 6,010,718 also assigned to Abbott describes an extended release pharmaceutical dosage form for clarithromycin, using from about 5 to about 50% by weight of a pharmaceutically acceptable polymer. The formulations described in this patent result not only in AUC and Cmin values similar to that of immediate release formulations administered twice daily, but also result in statistically significantly lower Cmax values. The total weight of the formulation as exemplified in this invention is close to 1000 mg for a tablet containing 500 mg drug. Once again, a single tablet would be unacceptably large at 2000mg thus necessitating the administration of two tablets of 500mg strength each for delivering the daily dose of 1000mg clarithromycin.

US 4,808,411 assigned to Abbott Laboratories claims a composition comprising from about 25% to about 95% of erythromycin A or a derivative thereof, and from about 5% to about 75% of a carbomer. The specification of this patent describes that the compositions made according to this invention provide palatable dosages of antibiotics that have pharmacokinetics properties which are substantially equivalent to commercially available immediate-release tablet and capsule formulations.

Accordingly, none of the oral controlled drug delivery systems heretofore described is completely satisfactory. Our co-pending application No. 2660/Del/97 describes a dosage form which is retained in the stomach for extended period of time and can deliver drugs to

the stomach at a controlled rate. This delivery system is particularly useful for drugs which are stable in the acidic milieu of the stomach and which have a window of drug absorption from upper parts of gastro-intestinal in the stomach. The dosage form described in this application utilizes a unique combination of gel forming polymers, viscosity enhancing agents, hydrophilic polymers and gas generating agent. This application has however not explored the use of such systems for controlling the release of acid degradable drugs.

It is an object of the present invention to provide a process for the preparation of a controlled release formulation for erythromycin or derivatives thereof that can deliver a daily dose of the drug in a single unit dosage form and wherein the rate controlling polymers are present at very small amounts of from about 0.1 to 4.0% w/w of the total weight of the dosage form, and wherein the delivery system maintains its physical integrity and a monolithic form when contacted with an aqueous media.

It is a further object of the present invention to provide a process for the preparation of a controlled release formulation for once daily administration of erythromycin or derivatives thereof, that contains a high dose medicament and is of an acceptable size which is convenient for oral administration. The use of small amounts of polymers ensures that total weight of the dosage form is low and a single dosage unit is sufficient to provide the therapeutic dosage of the drug compared to two units which need to be administered if the teachings of the prior art are to be followed. The present invention provides obvious benefits with respect to better patient convenience and therefore patient compliance.

The present invention provides a process for the preparation of a controlled release formulation of erythromycin or derivatives thereof for once daily administration comprising mixing a pharmaceutically effective amount of the drug with about 0.1% w/w to about 4.0% w/w of a pharmaceutically acceptable rate controlling polymer(s).

More preferably, the present invention provides a process for the preparation of a controlled release formulation of clarithromycin for once daily administration comprising mixing a pharmaceutically effective amount of drug with from about 0.1% w/w to about 4.0% w/w of a pharmaceutically acceptable rate controlling polymer(s).

Clarithromycin used in accordance with the present invention comprises 10-90% w/w of the total formulation weight. More preferably, it constitutes 50-90% w/w of the formulation.

The pharmaceutically acceptable rate controlling polymers used in accordance with the present invention comprises of carbohydrate gums, polyuronic acid salts, cellulose ethers, acrylic acid polymers and mixtures thereof.

Carbohydrate gums may be selected from amongst xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, sclero gum and the like. These gums upon contact with the gastro intestinal fluid form a viscous gel and help in maintaining the tablet integrity and sustaining the release of the drug even when used in very small amounts. In preferred embodiments of this invention, the carbohydrate used gum used is "xanthan gum" which is extraordinarily enzymatically resistant.

Examples of polyuronic acid salts that may be used in the present invention include alkali metal salts of alginic acid, alkali metal salts of pectic acid and mixtures thereof. In preferred embodiments of this invention, the water soluble salt of polyuronic acid is a salt of alginic acid, which is a mixture of two polyuronic acids, namely mannuoronic acid and gulucronic acid. Examples of alkali metal salts of alginic acid that may be used in the present invention include sodium alginate, potassium alginate, ammonium alginate, and the like. Importantly, when the pharmaceutical composition contains a water soluble salt of one or more polyuronic acids preferably a salt of alginic acid, it should be free of calcium ions.

The cellulose ethers used in accordance with the present invention include hydroxypropyl methylcellulose, hydroxypropyl cellulose, and the like. The polyacrylic acid polymers used may be such as is available under the brand name Carbopol (B.F. Goodrich, USA).

In addition to the water soluble rate controlling polymers, the composition may additionally contain about 6 to 50% w/w of other pharmaceutically acceptable excipients such as gas generating components, swelling agents, lubricants and fillers.

The gas generating components may constitute a single substance known to produce gas upon contact with gastric fluid, or may consist of a gas generating couple. Examples of the gas generating component that may be used in the present invention include carbonates, such as calcium carbonate or sodium glycine carbonate, bicarbonates, such as sodium hydrogen carbonate or potassium hydrogen carbonate, sulfites, such as

sodium sulfite, sodium bisulfite or sodium metabisulfite, and the like. The gas generating component interacts with an acid source triggered by contact with water or simply gastric fluid to generate gas. These salts can be used alone or in combination with an acid source as a couple. Examples of organic acids that may be used as an acid source include citric acid or its salts such as sodium or calcium citrate, malic acid, tartaric acid, succinic acid, fumaric acid, maleic acid or their salts, ascorbic acid and its salts such as sodium or calcium ascorbate. The organic acid salts include mono or bialkali salts of organic acids having one or more than one carboxylic groups. Most preferably the gas generating agent is sodium bicarbonate. The gas generating components may be present at 5-45% w/w of the total weight of the formulation.

The swelling agent is one which is capable of swelling to greater than its original volume when coming into contact with an aqueous fluid such as the gastrointestinal fluid. Examples of such swelling agents that may be used in the present invention include cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose sodium, sodium starch glycolate, and the like. This class of compounds is also known as superdisintegrants and is present in an amount of from about 5 to about 25% w/w of the formulation. More preferably, it is present in an amount from about 10% to about 20% w/w of the total weight of the formulation.

The composition according to the present invention also contains pharmaceutically acceptable lubricants such as those selected from amongst talc, calcium stearate, magnesium stearate, polyethylene glycols, silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate and mixtures thereof.

The composition according to the present invention also contains fillers selected from amongst those conventionally used in the art such as lactose, starches, glucose, sucrose, mannitol, silicic acid and mixtures thereof. Fillers are present at about 5% to about 15% w/w of the formulation.

According to the present invention, the pharmaceutical composition can incorporate a high dose medicament. The amount of drug used in the composition varies from about 100 to 1000 mg and the total weight of the tablet does not exceed more than 1500 mg, such that the drug is present upto 90% w/w of formulation. More preferably, the drug constitutes from about 50 to about 90% w/w of the formulation. The tablets made according to the

present invention are unique as they carry a very high payload of the drug and use very small amounts of polymers for controlling the drug release while at the same time maintaining the integrity of the tablet for extended periods of time.

The composition according to the present invention may be formulated as a capsule or tablet. Most preferably, the composition is a tablet. The tablet made according to the present invention may optionally be coated with a thin layer of a rapidly dissolving water soluble polymer or a pharmaceutical excipient.

The examples given herein further illustrate the invention and are not intended to limit the scope of the invention.

EXAMPLE 1

Table 1.1

Ingredients	mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1000.0	81.0
Sodium Alginate (LVCR)	12.5	1.0
Xanthan Gum	37.5	3.0
Cross-linked polyvinyl Pyrrolidone (CL-PVP)	125.0	10.1
Magnesium Stearate	12.5	1.0
Talc	20.0	1.6
Sodium stearyl fumarate	20.0	1.6
Aerosil 200	8.0	0.70
Purified water	Qs	qs
Total weight	1235.5	100.0

Clarithromycin, sodium alginate, xanthan gum and CL-PVP were sieved through a British Standard Sieve (BSS) 44 mesh sieve and blended together followed by granulation with water. The granules were dried in a fluid bed drier at 60°C for 20 minutes. The dried granules were sifted through a BSS 16 mesh sieve. The granules obtained were lubricated with the remaining ingredients namely talc, magnesium stearate, sodium stearyl fumarate and aerosil 200 and compressed to tablets.

The drug release from the tablets was monitored at pH 5.0 acetate buffer in USP apparatus II at 100 rpm and the results obtained are given in Table 1.2.

Table 1.2

Time (h)	Cumulative Percent drug released
1	19.0
2	27.0
4	40.0
6	45.0
8	51.0
10	55.0

The drug release was extended to more than 10 hours despite the use of only 4% w/w of the total rate controlling polymers indicating the efficacy of control. Release of only 55% of the drug in ten hours, was however unacceptably slow. The formulation was therefore modified to include a gas generating component to accelerate the rate of drug release as described in the next experiment.

EXAMPLE 2

Table 2.1

Ingredients	mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1000.0	75.0
Sodium bicarbonate	100.0	7.5
Sodium Alginate (LVCR)	50.0	3.7
Cross-linked polyvinyl Pyrrolidone (CL-PVP)	125.0	9.40
Magnesium Stearate	12.5	0.90
Talc	20.0	1.5
Sodium stearyl fumarate	20.0	1.5
Aerosil 200	8.0	0.6
Purified Water	Qs	qs
Total weight	1335.5	100.0

Tablets were made by the same process as described in Example 1 and evaluated for drug release (Table 2.2).

Table 2.2

Percent drug released in pH 5.0 acetate buffer in USP apparatus II at 100 rpm.

Time (h)	Cumulative Percent drug released
1	21.0
2	30.0
4	48.0
6	78.0
8	85.0
10	87.0

EXAMPLE 3

Table 3.1

Ingredients	mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1000.0	75.0
Hydroxypropyl methylcellulose (HPMC K100 MCR)	50.0	3.7
Sodium bicarbonate	100.0	7.5
Cross-linked polyvinyl Pyrrolidone (CL-PVP)	125.0	9.4
Magnesium Stearate	12.5	0.9
Talc	20.0	1.5
Sodium Stearyl Fumarate	20.0	1.5
Aerosil 200	8.0	0.6
Purified water	qs	qs
Total wt.	1335.5	100.0

Tablets were made following the same process that described in Example 1, and subjected to dissolution testing in USP apparatus II, at 100 rpm in pH 5.0 acetate buffer. The dissolution profile is given in Table 3.2.

Table 3.2

Time (h)	Cumulative Percent drug released
1	25.0
2	36.0
4	54.0
6	64.0
8	73.0
10	76.0

EXAMPLE 4**Table 4.1**

Ingredients	mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1000.0	84.3
Hydroxypropyl methylcellulose (HPMC K100MCR)	12.5	1.1
Sodium bicarbonate	100.0	8.4
Magnesium Stearate	12.5	1.1
Talc	10.0	0.8
Sodium Stearyl fumarate	20.0	1.7
Aerosil 200	5.0	0.4
Purified water	qs	qs
Total weight	1185.5	100.0

The tablets were made as described in Example 1. Only 1% HPMC was used as the rate controlling polymer. Tablets made according to the present example containing only 1% of rate controlling polymer were not only able to maintain their monolithic form, but were also capable of controlling the release of clarithromycin over an extended period of time as shown in Table 4.2.

Table 4.2

Time (h)	Percent drug released
1	7.0
2	12.0
4	16.0
6	24.0
8	53.0

EXAMPLE 5**Table 5.1**

Ingredients	mg/tab	Percent w/w of tablet weight
Clarithromycin equivalent to	1019.0	80.3
Sodium alginate (LVCR)	12.5	1.1
Xanthan Gum	37.5	3.01
Sodium bicarbonate	100.0	8.0
Magnesium Stearate	20.0	1.6
Talc	20.0	1.6
Sodium stearyl fumarate	30.0	2.4
Aerosil 200	5.0	0.4
Purified water	qs	qs
Total weight	1244.8	100.0

Tablets were made as described in Example 1 and Table 5.2 gives the dissolution profile of these tablets in pH 5.0 acetate buffer, USP apparatus II at 100 rpm.

Table 5.2

Time (h)	Cumulative Percent drug released
1	5
2	13
4	29
6	48
8	62
10	70

CLAIMS :

1. A process for the preparation of a controlled release formulation of erythromycin A or a derivatives thereof, suitable for once daily administration comprising mixing a pharmaceutically effective amount of erythromycin with from about 0.1% to about 4% w/w of pharmaceutically acceptable rate controlling polymer (s).
2. A process for the preparation of a controlled release formulation of clarithromycin suitable for once daily administration comprising mixing a pharmaceutically effective amount of clarithromycin with from about 0.1% to about 4% w/w of pharmaceutically acceptable rate controlling polymer (s).
3. A process as described in claims 1 and 2 wherein erythromycin A or its derivative comprises about 10% w/w to about 90% w/w of the total tablet weight.
4. A process as described in claim 3 wherein erythromycin A or its derivative preferably comprises about 50% w/w to about 90% w/w of the total tablet weight.
5. A process as described in claims 1 and 2 wherein the pharmaceutically acceptable rate controlling polymer comprises of carbohydrate gums, polyuronic acid salts, cellulose ethers, acrylic acid polymers, and mixtures thereof.
6. A process as described in claim 5 wherein the carbohydrate gums is selected from the group consisting of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, sclero gum, and mixtures thereof.
7. A process as described in claim 5 wherein the polyuronic acid salts are selected from the group consisting of alkali metal salts of pectic acid, alkali metal salts of alginic acid and mixtures thereof.
8. A process as described in claim 7 wherein the polyuronic acid salt is preferably sodium alginate.
9. A process as described in claim 5 wherein the cellulose ethers are selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, and mixtures thereof.
10. A process as described in claim 5 wherein the acrylic acid polymer is carbopol.
11. A process as described in claims 1 and 2 wherein the formulation may additionally contain other pharmaceutically acceptable excipients such as gas generating components, swelling agents, lubricants and fillers.
12. A process as described in claim 11, wherein the gas generating component is selected from the group consisting of sodium bicarbonate, calcium carbonate,

sodium carbonate and mixtures thereof either alone or in combination with an organic acid as a couple.

13. A process as described in claim 12, wherein the organic acid is selected from the group comprising citric acid, malic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, ascorbic acid and their salts.
14. A process as described in claim 12 wherein the gas generating component is preferably sodium bicarbonate.
15. A process as described in claim 12, wherein the gas generating agent comprises about 5% w/w to about 15% w/w of the tablet.
16. A process as described in claim 11 wherein the swelling agent is selected from the group consisting of cross-linked polyvinyl pyrrolidone, cross-linked carboxymethylcellulose sodium, sodium starch glycolate and mixtures thereof.
17. A process as described in claim 16 wherein the swelling agent comprises about 5% w/w to about 25% w/w of the tablet.
18. A process as described in claim 11 wherein the fillers are selected from the group consisting of monosaccharides, disaccharides and polysaccharides.
19. A process as described in claim 18 wherein the fillers comprises about 5% w/w to about 15% w/w of the tablet.
20. A process as described in claims 11 wherein the lubricants are selected from amongst the group consisting of talc, calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate and mixtures thereof.
21. A process as described in claims 1 and 2 wherein the controlled release formulation may be a tablet or a capsule.
22. A process as described in claim 21 wherein the formulation is a tablet.
23. A process as described in claim 22 wherein the tablet is optionally coated.
24. A process of making a monolithic formulation of clarithromycin comprising 100-1000 mg of clarithromycin, wherein the total weight of the dosage unit is not more than 1500 mg.
25. A process of making a formulation of clarithromycin wherein about 50 - 90% w/w clarithromycin is mixed with about 0.1 -4% w/w of pharmaceutically acceptable rate controlling polymers and about 6 - 50% w/w of other pharmaceutically acceptable excipients.

26. A process as described in claim 25 wherein the pharmaceutically acceptable rate controlling polymer comprises of carbohydrate gums, polyuronic acid salts, cellulose ethers, acrylic acid polymers, and mixtures thereof.
27. A process as described in claim 26 wherein the carbohydrate gums is selected from the group consisting of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, sclero gum, and mixtures thereof.
28. A process as described in claim 26 wherein the polyuronic acid salts are selected from the group consisting of alkali metal salts of pectic acid, alkali metal salts of alginic acid and mixtures thereof.
29. A process as described in claim 28 wherein the polyuronic acid salt is preferably sodium alginate.
30. A process as described in claim 26 wherein the cellulose ethers are selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, and mixtures thereof.
31. A process as described in claim 26 wherein the acrylic acid polymer is carbopol.
32. A process as described in claim 25 wherein the formulation may additionally contain other pharmaceutically acceptable excipients such as gas generating components, swelling agents, lubricants and fillers.
33. A process as described in claim 32, wherein the gas generating component is selected from the group consisting of sodium bicarbonate, calcium carbonate, sodium carbonate and mixtures thereof either alone or in combination with an organic acid as a couple.
34. A process as described in claim 33, wherein the organic acid is selected from the group comprising citric acid, malic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, ascorbic acid and their salts.
35. A process as described in claim 33 wherein the gas generating component is preferably sodium bicarbonate.
36. A process as described in claim 33, wherein the gas generating agent comprises about 5% w/w to about 15% w/w of the tablet.
37. A process as described in claim 32 wherein the swelling agent is selected from the group consisting of cross-linked polyvinyl pyrrolidone, cross-linked carboxymethylcellulose sodium, sodium starch glycolate and mixtures thereof.
38. A process as described in claim 37 wherein the swelling agent comprises about 5% w/w to about 25% w/w of the tablet.

39. A process as described in claim 32 wherein the fillers are selected from the group consisting of monosaccharides, disaccharides and polysaccharides.
40. A process as described in claim 39 wherein the fillers comprises about 5% w/w to about 15% w/w of the tablet.
41. A process as described in claims 32 wherein the lubricants are selected from amongst the group consisting of talc, calcium stearate, magnesium stearate, polyethylene glycol, sodium stearyl fumarate, sodium lauryl sulfate and mixtures thereof.
42. A process for the preparation of a controlled release formulation of clarithromycin suitable for once daily administration substantially as herein described and illustrated by the examples herein.

Dated this 29th day of August, 2000.

For Ranbaxy Laboratories Limited


(S K Patawari)
Company Secretary